• homeHome
  • First Menu Shortcut OpenNewsroom
  • Secound Menu Shortcut OpenCompany News
  • Last Menu Shortcut Open Media Focus
UPDATE | August 22, 2022

Samsung Biologics, C&T invest in US biotech firm Senda Biosciences

  • MAIL

0812%20The_Korea_Times.jpg
 

An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their efforts to foster core technology required to develop next-generation biopharmaceuticals, Samsung Biologics said on Wednesday.

Samsung Biologics said the Life Science Fund, jointly formed by itself and Samsung C&T, decided to invest in Senda Biosciences, recognizing that the U.S. company has secured a superior programmable drug delivery platform. 

 

Read more 

0812%20The_Korea_Times.jpg
 

An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their efforts to foster core technology required to develop next-generation biopharmaceuticals, Samsung Biologics said on Wednesday.

Samsung Biologics said the Life Science Fund, jointly formed by itself and Samsung C&T, decided to invest in Senda Biosciences, recognizing that the U.S. company has secured a superior programmable drug delivery platform. 

 

Read more

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required